SlideShare ist ein Scribd-Unternehmen logo
1 von 42
Our Perspective on Endoscopic Resection for Colorectal Neoplasms 11-12 February, 2011, ROME Takahisa Matsuda, M.D, Ph.D National Cancer Center Hospital, Tokyo Endoscopy Division - Piecemeal EMR/ ESD - 3rd course on  E NDOSCOPY   IN GASTROINTESTINAL ONCOLOGY
[object Object],Introduction ,[object Object],[object Object],[object Object],[object Object],[object Object]
National Cancer Center Hospital, Tokyo During Screening Colonoscopy…
How to Decide the “Therapeutic Plan”? - Endoscopic Treatment? Surgical Operation? EMR LN EMR Local resection  without  LN dissection Surgery Local resection  with  LN dissection Surgery LN
EMR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Risk factors of lymph node metastasis (LNM)* - Endoscopic Treatment? Surgical Operation? * Paris Classification, Gastrointest Endosc 2003 How to Decide the “Therapeutic Plan”?
Importance of Estimation of SM Invasion Risk factors for lymph node metastasis in patients with submucosal cancer O   We can predict only the  “Depth of Invasion” X   Lymphovascular invasion X  P/D adenocarcinoma Vascular involvement (+) Submucosal deep invasion (+)
Pre-operative Endoscopic  Depth Diagnosis Magnifying Colonoscopy  Pit Pattern (Kudo’s) Classification Matsuda T, Fujii T, Saito Y, et al : Am J Gastroenterol, 2008 Endoscopic Treatment  (EMR) Operation (OPE) No Treatment
& Demarcated area Irregular, distorted crypts 0.05% Crystal violet staining There is a strong relationship between this pattern and invasive cancer Demarcated area Irregular, distorted      crypts Invasive pattern
Non-Invasive pattern Almost all the lesions of this pattern are intra-mucosal lesions (LGD or HGD)
LST-NG  LST-NG  IIa (< 5mm) LST-G  IIa (5-10mm) LST (> 10mm) * LST: laterally spreading tumor;  “Flat elevated lesion >10mm” Non-polypoid (Flat & Depressed) CRNs are Current Topic Clinically, it is very important “How to manage these LST lesions”. Flat Lesions
Relationship Between Lesion Size and Clinicopathological Findings -  1989 Flat early stage colorectal neoplasms, NCCH, 1998-2003  - Adenoma (LGD) M-SM Ca Size Pathology (HGD- Early Invasive ca) Location (C/A/T: D/S: R) 508:288:34 387:276:43 260:111:82 ( 61% :35%:4%) ( 55% :39%:6%) ( 57% :25%:18%) Total 1155:675:159 ( 58% :34%:8%) Matsuda T, Saito Y, et al : Dig Endoscopy, 2010 Flat Lesions < 5mm (830) 5-10mm (706) ≥  10mm (453:  23% ) 828 (99.8%) 657 (93.1%) 203 (44.8%) 1688 (84.9%) 2 (0.2%) 49 (6.9%) 250 (55.2%) 301 (15.1%)
LST (Laterally spreading tumor) Saito Y, et al. Endoscopy 2001;33: 682-686.  - Subclassification of LSTs - LST-granular (LST-G) uniform type LST-granular (LST-G) mixed type LST-nongranular (LST-NG) LST-G LST-NG
LST-NG 10mm - 20mm - 30mm - 12/246 (4.9%) 24/106 (22.6%) 11/33 (33.3%) Total 55/402 (13.7%) 0/115 (0%) 0/70 (0%) 1/31 (3.2%) 1/227 LST-G (uniform) LST-G (mixed) 4/72 (5.6%) 6/70 (8.6%) 9/65 (13.8%) 44/321 (0.4%) (13.7%) 40mm - 8/17 (47.0%) 0/13 (0%) 25/114 (21.9%) Relationship Between the Size of LSTs  & the Rate of SM Invasion NCCH 1998-2006 Matsuda T, Saito Y, Conio M, et al : Gastroenterol Clin Biol, 2010
16 (84%) 3 (16%) 19 Under the large nodule Under the depressed area 9  (27%) 23 (72%) 32 Multifocal Under the depressed area LST-G LST-NG The Area of SM Penetration Uraoka T, Saito Y, Matsuda T, et al. Gut. 2006. The extent of SM penetration of LST-G is easy to diagnose endoscopically.  In contrast, the prediction of SM penetration of LST-NG is difficult.
EMR Strategy for LST LST-G En-bloc  Resection 1 st; As large as possible LST-NG Endoscopic piecemeal resection (EPMR) is feasible for LST-granular type.  In contrast, we should perform En-bloc resection for LST-non-granular type.
Treatment Strategy for Colorectal Neoplasms “ Based on the Lesion’s  SIZE ,  MACROSCOPIC TYPE  and  Estimated DEPTH of INVASION ” SIZE DEPTH of Invasion 2cm 4cm SM ca  1000 µ m LAC  (Laparoscopic Surgery) Open Surgery Conventional EMR Hot biopsy/ Polypectomy ESD EPMR M ca/ Adenoma Adv.ca (<5mm) (>5mm)
Rectum, 40mm, Is+IIa (LST-G: mixed type) Injected Solution:  Glycerol , Snare:  Snare master 25mm  (OYMPUS), Scope:  PCF240ZI  (OLYMPUS) Procedure Time: 15 min EPMR   (piecemeal EMR)
Hotta K, Saito Y, Matsuda T, et al. Int J Colorectal Dis. 2008 Local Recurrence Rate Size (mm) 10-19 20-29 30+ Total En-bloc Piecemeal Total 0.8% 0% 0% 0.7% (3/366) (0/65) (0/9) (3/440) 14.7% 21.7% 34.2% 23.5% (5/34) (13/60) (13/38) (31/132) 2.0% 10.4 % 27.7% 5.9% (8/400) (13/125) (13/47) (34/572)
A B C D E F G Recurrent Case: Rs, 50mm, Is+IIa (LST-G: mixed)  A-C:  Piecemeal EMR , W/D adenocarcinoma, pM (HGD) D-F: Follow-up CF (after 6M) -> Additional hot biopsy G: Follow-up CF (after 12M) -> No re-recurrence
Colorectal ESD Location: Ra, Size: 30mm, Macroscopic type: IIa+IIc
#10 -> O A  ← Mapping and Panoramic View #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #1
800μm #5   SM Invasion Desmin
#4   SM Invasion
Final Histopathological Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What’s the  Advantages  of ESD? ,[object Object],[object Object]
What’s the  Disadvantages  of ESD? ,[object Object],[object Object],[object Object]
Endoscopic Mucosal Resection  with Circumferential Incision
■   ESD Using Several Knives under CO 2  Insufflations              Ball tip B-knife IT knife CO2 insufflations COLORECTAL ESD PROCEDURE Zeon Medical Co. Olympus  Co. Olympus  Co. Colorectal ESD Olympus  Co. Dual knife Water jet Scope Olympus  Co.
Dual Knife  (OLYMPUS) ,[object Object],[object Object],[object Object],[object Object],[object Object],1.5mm
CO 2  Insufflations System  (OLYMPUS, UCR) CO2 Air
Virtual Colonoscopy Location: lower rectum (Rb) Size : 60mm Macroscopic type : 0-IIa (LST-G)
Conventional Endoscopy
Magnifying Endoscopy-NBI Capillary pattern: Type II (Sano’s classification)
Magnifying Chromoendoscopy Type IV/III L  pit (Kudo’s classification) Non-invasive pattern
ESD Procedure
Pathological findings ,[object Object],[object Object],[object Object],cf. The revised Vienna classification Category Diagnosis Clinically equivalent terms 3 Mucosal low-grade neoplasia LGIN, low grade adenoma/ dysplasia 4 Mucosal high-grade neoplasia 4. 1 HGIN, high-grade adenoma/ dysplasia 4. 2 HGIN, non-invasive carcinoma (CIS) 4. 3 Suspicious for invasive Ca. 4. 4 Intramucosal Ca 5 Submucosal or deeper invasion by carcinoma
* All cases except one treated without surgery Saito Y,  Uraoka T, Matsuda T et al. Gastrointest Endosc, 2010 Results of 500 Colorectal ESDs Macroscopic Type    Is, IIa+IIc, IIc, SMT LST-G LST-NG  Recurrent lesions 52 220 200 28 Location C: 35, Rt: 195, Lt: 130, R: 140 Size of Lesion (mean) 40      20mm (20-150mm) Procedure Time 90    73 (15-390) min.   En-bloc  Resection 88% Curative Resection 86% Complications    Perforation    Delayed Bleeding    13* (2.6%) 5 (1%) Histopathology Adenoma: 127, M-SM1: 315, SM2-: 55
National Cancer Center Hospital, Tokyo How often should we choose ESD? The Prevalence of Suitable Lesions for ESD
*  LSTs: LST-G and LST-NG ** Definite indication: LST-NG lesion ≥20 mm §  Relative indication: LST-G Mixed type [Is+IIa (LST-G)] ≥40 mm Matsuda T, Saito Y, Conio M, et al. Gastroenterol Clin Biol 2010 National Cancer Center Hospital, Tokyo, 1998-2006  The Prevalence of Suitable Lesions for ESD All Neoplastic Lesions ( n  = 11,488) Early Colorectal Cancers ( n  = 1,691) LSTs * 5.9%  ( n  = 674) 22.6%  ( n  = 382) Indication for ESD 2.3%   ( n  = 267) 12.1%   ( n  = 205) Definite indication ** for ESD 1.0%   ( n  = 115) 5.0%   ( n  = 85) Relative indication § for ESD 1.3%  ( n  = 152) 7.1%  ( n  = 120)
Endoscopic Depth Diagnosis is Important! All lesions are SM deep invasive cancer!
Conclusion ,[object Object],[object Object],[object Object]
Thank you for your kind attention! Takahisa Matsuda M.D., Ph.D. National Cancer Center Hospital, Tokyo Endoscopy Division E-mail: tamatsud@ncc.go.jp

Weitere ähnliche Inhalte

Was ist angesagt?

immunotherapy and PDL1 IHC
immunotherapy and PDL1 IHCimmunotherapy and PDL1 IHC
immunotherapy and PDL1 IHCkanwalpreet15
 
Approach to undifferentiated tumors
Approach to undifferentiated tumorsApproach to undifferentiated tumors
Approach to undifferentiated tumorsDr. Varughese George
 
Oncotype dx presentation
Oncotype dx presentationOncotype dx presentation
Oncotype dx presentationahmed mjali
 
Oncotype Dx Mammaprint
Oncotype Dx MammaprintOncotype Dx Mammaprint
Oncotype Dx Mammaprintfondas vakalis
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERAaditya Prakash
 
MICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCER
MICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCERMICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCER
MICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCERravi jaiswal
 
Early breast cancer management
Early breast cancer managementEarly breast cancer management
Early breast cancer managementWoraprat Samart
 
Management of testicular cancers
Management of testicular cancersManagement of testicular cancers
Management of testicular cancersMohd Waseem Raza
 
Serrated lesions of colon and rectum
Serrated lesions of colon and rectumSerrated lesions of colon and rectum
Serrated lesions of colon and rectumDr Snehal Kosale
 
Immunotherapy advances in lung cancer
Immunotherapy advances in lung cancerImmunotherapy advances in lung cancer
Immunotherapy advances in lung cancerAlok Gupta
 
Carcinoma of unknown primary devnani
Carcinoma of unknown primary devnaniCarcinoma of unknown primary devnani
Carcinoma of unknown primary devnaniBharti Devnani
 
Targeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinomaTargeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinomaMohammed Abd El Wadood
 
Recent advances in targeted therapy for metastatic lung cancer
Recent advances in targeted therapy for metastatic lung cancerRecent advances in targeted therapy for metastatic lung cancer
Recent advances in targeted therapy for metastatic lung cancerAlok Gupta
 
New response evaluation criteria in solid tumours
New response evaluation criteria in solid tumours New response evaluation criteria in solid tumours
New response evaluation criteria in solid tumours Ameen Rageh
 

Was ist angesagt? (20)

immunotherapy and PDL1 IHC
immunotherapy and PDL1 IHCimmunotherapy and PDL1 IHC
immunotherapy and PDL1 IHC
 
Thymoma
ThymomaThymoma
Thymoma
 
Carcinoma of Unknown Primary (COUP)
Carcinoma of Unknown Primary (COUP)Carcinoma of Unknown Primary (COUP)
Carcinoma of Unknown Primary (COUP)
 
Approach to undifferentiated tumors
Approach to undifferentiated tumorsApproach to undifferentiated tumors
Approach to undifferentiated tumors
 
Oncotype dx presentation
Oncotype dx presentationOncotype dx presentation
Oncotype dx presentation
 
Oncotype Dx Mammaprint
Oncotype Dx MammaprintOncotype Dx Mammaprint
Oncotype Dx Mammaprint
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCER
 
MICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCER
MICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCERMICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCER
MICROSATELLITE INSTABILTY - CLINICAL RELEVANCE IN COLO RECTAL CANCER
 
Early breast cancer management
Early breast cancer managementEarly breast cancer management
Early breast cancer management
 
Management of testicular cancers
Management of testicular cancersManagement of testicular cancers
Management of testicular cancers
 
Serrated lesions of colon and rectum
Serrated lesions of colon and rectumSerrated lesions of colon and rectum
Serrated lesions of colon and rectum
 
Targeted Therapy in Cancer
Targeted Therapy in Cancer Targeted Therapy in Cancer
Targeted Therapy in Cancer
 
Immunotherapy advances in lung cancer
Immunotherapy advances in lung cancerImmunotherapy advances in lung cancer
Immunotherapy advances in lung cancer
 
FNAC of breast
FNAC of breastFNAC of breast
FNAC of breast
 
Carcinoma of unknown primary devnani
Carcinoma of unknown primary devnaniCarcinoma of unknown primary devnani
Carcinoma of unknown primary devnani
 
Targeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinomaTargeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinoma
 
Recent advances in targeted therapy for metastatic lung cancer
Recent advances in targeted therapy for metastatic lung cancerRecent advances in targeted therapy for metastatic lung cancer
Recent advances in targeted therapy for metastatic lung cancer
 
New response evaluation criteria in solid tumours
New response evaluation criteria in solid tumours New response evaluation criteria in solid tumours
New response evaluation criteria in solid tumours
 
Grossing of breast
Grossing of breastGrossing of breast
Grossing of breast
 
Oligometastases
OligometastasesOligometastases
Oligometastases
 

Ähnlich wie Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD

Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD
Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD
Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD European School of Oncology
 
Preoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue SarcomaPreoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue Sarcomafondas vakalis
 
Histological Distinction between the Granular and Nongranular Types of Latera...
Histological Distinction between the Granular and Nongranular Types of Latera...Histological Distinction between the Granular and Nongranular Types of Latera...
Histological Distinction between the Granular and Nongranular Types of Latera...Goto Pablo
 
Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...Saeed Al-Shomimi
 
Endometrial Carcinoma.Adjuvant Treatment
Endometrial Carcinoma.Adjuvant TreatmentEndometrial Carcinoma.Adjuvant Treatment
Endometrial Carcinoma.Adjuvant Treatmentbalaganoff
 
ECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - Surgery
ECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - SurgeryECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - Surgery
ECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - SurgeryEuropean School of Oncology
 
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology European School of Oncology
 
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology European School of Oncology
 
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology European School of Oncology
 
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung CancerYong Chan Ahn
 
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...European School of Oncology
 
IORT_ in vivo dosimetry
IORT_ in vivo dosimetryIORT_ in vivo dosimetry
IORT_ in vivo dosimetrylararalferri
 

Ähnlich wie Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD (20)

Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD
Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD
Endoscopy in Gastrointestinal Oncology - Slide 4 - I. Oda - Esophageal ESD
 
Preoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue SarcomaPreoperative Radiotherapy In Extremity Soft Tissue Sarcoma
Preoperative Radiotherapy In Extremity Soft Tissue Sarcoma
 
MCC 2011 - Slide 28
MCC 2011 - Slide 28MCC 2011 - Slide 28
MCC 2011 - Slide 28
 
Ewing sarcoma
Ewing sarcomaEwing sarcoma
Ewing sarcoma
 
Histological Distinction between the Granular and Nongranular Types of Latera...
Histological Distinction between the Granular and Nongranular Types of Latera...Histological Distinction between the Granular and Nongranular Types of Latera...
Histological Distinction between the Granular and Nongranular Types of Latera...
 
Gi tumour
Gi tumourGi tumour
Gi tumour
 
Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...Can we apply the same indications of ESD for primary gastric cancer to remnan...
Can we apply the same indications of ESD for primary gastric cancer to remnan...
 
4 dr mario sideri m k
4  dr mario sideri  m k4  dr mario sideri  m k
4 dr mario sideri m k
 
G. Ceresoli - Lung cancer - State of the art
G. Ceresoli - Lung cancer - State of the artG. Ceresoli - Lung cancer - State of the art
G. Ceresoli - Lung cancer - State of the art
 
Endometrial Carcinoma.Adjuvant Treatment
Endometrial Carcinoma.Adjuvant TreatmentEndometrial Carcinoma.Adjuvant Treatment
Endometrial Carcinoma.Adjuvant Treatment
 
Orthopaedic oncology
Orthopaedic oncologyOrthopaedic oncology
Orthopaedic oncology
 
Bone tumors
Bone tumorsBone tumors
Bone tumors
 
ECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - Surgery
ECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - SurgeryECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - Surgery
ECCLU 2011 - G. Thalmann - Localised invasive bladder cancer - Surgery
 
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
 
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology
 
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
BALKAN MCO 2011 - G. Cserni - Epidemiology and pathology
 
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
1411 APLCC AHNYC SBRT & IMRT in Lung Cancer
 
Ewings tumour
Ewings tumourEwings tumour
Ewings tumour
 
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
 
IORT_ in vivo dosimetry
IORT_ in vivo dosimetryIORT_ in vivo dosimetry
IORT_ in vivo dosimetry
 

Mehr von European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Mehr von European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

Endoscopy in Gastrointestinal Oncology - Slide 18 - T. Matsuda - Colorectal ESD

  • 1. Our Perspective on Endoscopic Resection for Colorectal Neoplasms 11-12 February, 2011, ROME Takahisa Matsuda, M.D, Ph.D National Cancer Center Hospital, Tokyo Endoscopy Division - Piecemeal EMR/ ESD - 3rd course on E NDOSCOPY IN GASTROINTESTINAL ONCOLOGY
  • 2.
  • 3. National Cancer Center Hospital, Tokyo During Screening Colonoscopy…
  • 4. How to Decide the “Therapeutic Plan”? - Endoscopic Treatment? Surgical Operation? EMR LN EMR Local resection without LN dissection Surgery Local resection with LN dissection Surgery LN
  • 5.
  • 6. Importance of Estimation of SM Invasion Risk factors for lymph node metastasis in patients with submucosal cancer O We can predict only the “Depth of Invasion” X Lymphovascular invasion X P/D adenocarcinoma Vascular involvement (+) Submucosal deep invasion (+)
  • 7. Pre-operative Endoscopic Depth Diagnosis Magnifying Colonoscopy Pit Pattern (Kudo’s) Classification Matsuda T, Fujii T, Saito Y, et al : Am J Gastroenterol, 2008 Endoscopic Treatment (EMR) Operation (OPE) No Treatment
  • 8. & Demarcated area Irregular, distorted crypts 0.05% Crystal violet staining There is a strong relationship between this pattern and invasive cancer Demarcated area Irregular, distorted    crypts Invasive pattern
  • 9. Non-Invasive pattern Almost all the lesions of this pattern are intra-mucosal lesions (LGD or HGD)
  • 10. LST-NG LST-NG IIa (< 5mm) LST-G IIa (5-10mm) LST (> 10mm) * LST: laterally spreading tumor; “Flat elevated lesion >10mm” Non-polypoid (Flat & Depressed) CRNs are Current Topic Clinically, it is very important “How to manage these LST lesions”. Flat Lesions
  • 11. Relationship Between Lesion Size and Clinicopathological Findings - 1989 Flat early stage colorectal neoplasms, NCCH, 1998-2003 - Adenoma (LGD) M-SM Ca Size Pathology (HGD- Early Invasive ca) Location (C/A/T: D/S: R) 508:288:34 387:276:43 260:111:82 ( 61% :35%:4%) ( 55% :39%:6%) ( 57% :25%:18%) Total 1155:675:159 ( 58% :34%:8%) Matsuda T, Saito Y, et al : Dig Endoscopy, 2010 Flat Lesions < 5mm (830) 5-10mm (706) ≥ 10mm (453: 23% ) 828 (99.8%) 657 (93.1%) 203 (44.8%) 1688 (84.9%) 2 (0.2%) 49 (6.9%) 250 (55.2%) 301 (15.1%)
  • 12. LST (Laterally spreading tumor) Saito Y, et al. Endoscopy 2001;33: 682-686. - Subclassification of LSTs - LST-granular (LST-G) uniform type LST-granular (LST-G) mixed type LST-nongranular (LST-NG) LST-G LST-NG
  • 13. LST-NG 10mm - 20mm - 30mm - 12/246 (4.9%) 24/106 (22.6%) 11/33 (33.3%) Total 55/402 (13.7%) 0/115 (0%) 0/70 (0%) 1/31 (3.2%) 1/227 LST-G (uniform) LST-G (mixed) 4/72 (5.6%) 6/70 (8.6%) 9/65 (13.8%) 44/321 (0.4%) (13.7%) 40mm - 8/17 (47.0%) 0/13 (0%) 25/114 (21.9%) Relationship Between the Size of LSTs & the Rate of SM Invasion NCCH 1998-2006 Matsuda T, Saito Y, Conio M, et al : Gastroenterol Clin Biol, 2010
  • 14. 16 (84%) 3 (16%) 19 Under the large nodule Under the depressed area 9 (27%) 23 (72%) 32 Multifocal Under the depressed area LST-G LST-NG The Area of SM Penetration Uraoka T, Saito Y, Matsuda T, et al. Gut. 2006. The extent of SM penetration of LST-G is easy to diagnose endoscopically. In contrast, the prediction of SM penetration of LST-NG is difficult.
  • 15. EMR Strategy for LST LST-G En-bloc Resection 1 st; As large as possible LST-NG Endoscopic piecemeal resection (EPMR) is feasible for LST-granular type. In contrast, we should perform En-bloc resection for LST-non-granular type.
  • 16. Treatment Strategy for Colorectal Neoplasms “ Based on the Lesion’s SIZE , MACROSCOPIC TYPE and Estimated DEPTH of INVASION ” SIZE DEPTH of Invasion 2cm 4cm SM ca 1000 µ m LAC (Laparoscopic Surgery) Open Surgery Conventional EMR Hot biopsy/ Polypectomy ESD EPMR M ca/ Adenoma Adv.ca (<5mm) (>5mm)
  • 17. Rectum, 40mm, Is+IIa (LST-G: mixed type) Injected Solution: Glycerol , Snare: Snare master 25mm (OYMPUS), Scope: PCF240ZI (OLYMPUS) Procedure Time: 15 min EPMR (piecemeal EMR)
  • 18. Hotta K, Saito Y, Matsuda T, et al. Int J Colorectal Dis. 2008 Local Recurrence Rate Size (mm) 10-19 20-29 30+ Total En-bloc Piecemeal Total 0.8% 0% 0% 0.7% (3/366) (0/65) (0/9) (3/440) 14.7% 21.7% 34.2% 23.5% (5/34) (13/60) (13/38) (31/132) 2.0% 10.4 % 27.7% 5.9% (8/400) (13/125) (13/47) (34/572)
  • 19. A B C D E F G Recurrent Case: Rs, 50mm, Is+IIa (LST-G: mixed) A-C: Piecemeal EMR , W/D adenocarcinoma, pM (HGD) D-F: Follow-up CF (after 6M) -> Additional hot biopsy G: Follow-up CF (after 12M) -> No re-recurrence
  • 20. Colorectal ESD Location: Ra, Size: 30mm, Macroscopic type: IIa+IIc
  • 21. #10 -> O A ← Mapping and Panoramic View #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #1
  • 22. 800μm #5   SM Invasion Desmin
  • 23. #4   SM Invasion
  • 24.
  • 25.
  • 26.
  • 27. Endoscopic Mucosal Resection with Circumferential Incision
  • 28. ESD Using Several Knives under CO 2 Insufflations            Ball tip B-knife IT knife CO2 insufflations COLORECTAL ESD PROCEDURE Zeon Medical Co. Olympus Co. Olympus Co. Colorectal ESD Olympus Co. Dual knife Water jet Scope Olympus Co.
  • 29.
  • 30. CO 2 Insufflations System (OLYMPUS, UCR) CO2 Air
  • 31. Virtual Colonoscopy Location: lower rectum (Rb) Size : 60mm Macroscopic type : 0-IIa (LST-G)
  • 33. Magnifying Endoscopy-NBI Capillary pattern: Type II (Sano’s classification)
  • 34. Magnifying Chromoendoscopy Type IV/III L pit (Kudo’s classification) Non-invasive pattern
  • 36.
  • 37. * All cases except one treated without surgery Saito Y, Uraoka T, Matsuda T et al. Gastrointest Endosc, 2010 Results of 500 Colorectal ESDs Macroscopic Type   Is, IIa+IIc, IIc, SMT LST-G LST-NG Recurrent lesions 52 220 200 28 Location C: 35, Rt: 195, Lt: 130, R: 140 Size of Lesion (mean) 40  20mm (20-150mm) Procedure Time 90  73 (15-390) min. En-bloc Resection 88% Curative Resection 86% Complications   Perforation   Delayed Bleeding    13* (2.6%) 5 (1%) Histopathology Adenoma: 127, M-SM1: 315, SM2-: 55
  • 38. National Cancer Center Hospital, Tokyo How often should we choose ESD? The Prevalence of Suitable Lesions for ESD
  • 39. * LSTs: LST-G and LST-NG ** Definite indication: LST-NG lesion ≥20 mm § Relative indication: LST-G Mixed type [Is+IIa (LST-G)] ≥40 mm Matsuda T, Saito Y, Conio M, et al. Gastroenterol Clin Biol 2010 National Cancer Center Hospital, Tokyo, 1998-2006 The Prevalence of Suitable Lesions for ESD All Neoplastic Lesions ( n = 11,488) Early Colorectal Cancers ( n = 1,691) LSTs * 5.9% ( n = 674) 22.6% ( n = 382) Indication for ESD 2.3% ( n = 267) 12.1% ( n = 205) Definite indication ** for ESD 1.0% ( n = 115) 5.0% ( n = 85) Relative indication § for ESD 1.3% ( n = 152) 7.1% ( n = 120)
  • 40. Endoscopic Depth Diagnosis is Important! All lesions are SM deep invasive cancer!
  • 41.
  • 42. Thank you for your kind attention! Takahisa Matsuda M.D., Ph.D. National Cancer Center Hospital, Tokyo Endoscopy Division E-mail: tamatsud@ncc.go.jp

Hinweis der Redaktion

  1. Thank you Mr. Chairman. Good afternoon ladies and gentleman. First of all, I would like to express my special thanks to the organizing committee especially Dr. Massimo for inviting me to this wonderful course. Today, I would like to talk about “Our perspective on endoscopic resection for colorectal neoplasms”.
  2. Of course, EMR is … In contrast, surgical operation is …
  3. So, EMR should be performed only for early CRC without risk of LNM or adenoma. According to the “Paris classification”, these 3 factors are considered as a risk of LNM. Of course, after EMR, we need to assess histopathologically. If it doesn’t meet this criteria, we need to recommend additional surgical operation.
  4. Endoscopically, we can predict only the “depth of invasion”. It is impossible to predict lymphovascular invasion and poorly differentiated adenocarcinoma component in advance.
  5. As I already mentioned, Non-polypoid CRNs are current topic. Among them,
  6. This is the relationship between the lesion size and clinicopathological findings. During this period, we treated 1989 flat early stage colorectal neoplasms in our center. Based on the lesion size, we divided into three groups. Surprisingly, about 60% lesions located in the right-sided colon. Among the lesions judged as less than 5mm, almost all lesions were LGD. In contrast, the lesions diagnosed as so-called LSTs, 55% were high grade dysplasia or early invasive cancer.
  7. As for the LST lesions, we usually classify into three groups. In short, LST-G uniform type, LST-G mixed type and LST-NG type.
  8. As you can see, the incidence of SM cancer in this LST-G uniform type is very low less than 1%. In contrast, in these groups, about 13% cases are SM invasive cancer. Especially, large LST-NG type over 20mm has high incidence of SM invasion.
  9. This is our treatment strategy for colorectal neoplasms. We usually decide the therapeutic plan based on the…
  10. This slide shows the results of 250 colorectal ESD cases. The mean size of the lesion was about 4cm, and mean procedure time was 1hr and half. The rate of En-bloc resection was 84%, and complication’s rate was totally 7%. But, fortunately all cases except one case treated without emergent operation.
  11. After introduction,